Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. (Q50555852)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 July 2011

Language	Label	Description	Also known as
English	Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.	scientific article published on 5 July 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

1 reference

based on heuristic

inferred from title

genetic variation

1 reference

based on heuristic

inferred from title

Kazuaki Chayama

13

object named as

Kazuaki Chayama

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Hiromitsu Kumada

15

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Fumitaka Suzuki

2

object named as

Fumitaka Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

12

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Masahiro Kobayashi

8

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Yoshiyuki Suzuki

6

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

1

object named as

Norio Akuta

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

11

object named as

Yasuji Arase

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

5

object named as

Hitomi Sezaki

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

10

object named as

Satoshi Saitoh

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Yusuke Kawamura

4

object named as

Yusuke Kawamura

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Mariko Kobayashi

9

object named as

Mariko Kobayashi

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

7

object named as

Tetsuya Hosaka

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

author name string

Miharu Hirakawa

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Yusuke Nakamura

14

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

publication date

5 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

55

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

3

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

231-241

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to Therapy

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Mutations in the hepatitis C virus core gene are associated with advanced liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

A high-throughput SNP typing system for genome-wide association studies

1 reference

https://api.crossref.org/works/10.1159%2F000328327

21 January 2018

Identifiers

10.1159/000328327

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/21734353

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50555852&oldid=2139237686"